The 60-day PDUFA clock creates a binary catalyst with a defined timeline. The FDA's prior conclusion that no additional trials are needed significantly de-risks approval. Monitor for labeling negotiations and any pre-approval inspection issues. The stock is likely to re-rate toward EU-approved product value ahead of the decision date.
Price Chart
Executive Summary
Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) to the FDA for the treatment of neovascular age-related macular degeneration (nAMD). The FDA Office of New Drugs previously concluded that substantial evidence of effectiveness has been established, and this is a Class 1 resubmission with a PDUFA decision expected within 60 days.
Key Facts
- BLA resubmitted to FDA on June 1, 2026 for ONS-5010/LYTENAVA (bevacizumab-vikg) for nAMD.
- FDA Office of New Drugs concluded substantial evidence of effectiveness has been established; no additional trials required.
- Class 1 resubmission with PDUFA decision expected within 60 days of FDA receipt.
- Product already has Marketing Authorization in the EU and UK; commercial launch commenced in Germany, Austria, and the UK.
- If approved, ONS-5010 would be the first FDA-approved ophthalmic formulation of bevacizumab.
Financial Impact
No financial figures provided in the filing; market cap is $111M. FDA approval would open the U.S. market for the first on-label ophthalmic bevacizumab, a multi-billion-dollar opportunity in anti-VEGF retinal therapies.
Risk Factors
- FDA could issue a new Complete Response Letter on manufacturing or labeling issues despite the favorable appeal outcome.
- Pricing and reimbursement in the U.S. may be lower than expected, limiting revenue potential.
- Competition from existing anti-VEGF agents (Eylea, Vabysmo, Lucentis) and biosimilars may pressure market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-068659 |
| Document: tm2616461d1_ex99-1.htm | 0001104659-26-068659 |
| Document: 0001104659-26-068659-index-headers.html | 0001104659-26-068659 |
| Document: 0001104659-26-068659-index.html | 0001104659-26-068659 |
| Document: 0001104659-26-068659.txt | 0001104659-26-068659 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5930 (+21.60%) |
Aug 14, 2026 7w ago | 424B5 | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5930 (+21.60%) |
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5930 (+21.60%) |
Aug 14, 2026 7w ago | Press Release | $0.7564 $0.6379 | ▼ −15.67% | ▼ −13.67% | $0.5930 (−21.60%) |
Aug 13, 2026 7w ago | Press Release | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5930 (+33.28%) |
Aug 12, 2026 7w ago | 8-K | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5930 (+33.28%) |
Jul 24, 2026 10w ago | 8-K | $1.07 $0.6090 | ▼ −42.82% | ▼ −46.12% | $0.5930 (−44.32%) |
Jul 24, 2026 10w ago | Press Release | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5930 (−57.79%) |
Jul 23, 2026 10w ago | 8-K | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5930 (−57.79%) |
Jul 22, 2026 10w ago | EFFECT | $1.34 $0.6901 | ▼ −48.50% | ▼ −51.40% | $0.5930 (−55.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access